HYPR Q3'26 Earnings: EPS estimate is (0.08) USD

Hyperfine (HYPR) will report Q3'26 earnings on November 09. Analysts expect revenue of $5.84M and a loss of $0.08 per share, according to estimates.

Original reporting
Published Nov 6, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HYPR Q3'26 Earnings: EPS estimate is (0.08) USD — source image
Decision brief

The 30-second read

$HYPRNeutralLow
01

Why it matters

The preview provides the only publicly available guidance ahead of the earnings release, creating a short‑term trading focus on the upcoming report.

02

Market read

Earnings preview for a micro‑cap creates limited but immediate relevance for traders watching the November 9 release.

03

What to watch

Potential regulatory approvals or new product launches not mentioned could offset a earnings shortfall.

Relevance 5/10Novelty 4/10Timing: post‑market November 9

Background

Hyperfine, Inc. (HYPR) is a small‑cap medical‑device company preparing to release its Q3'26 earnings after market close on November 9.

Company-level read

Ticker impact

$HYPRNeutralMedium confidence
Context

The article previews HYPR's upcoming Q3'26 earnings with revenue and EPS estimates, making the upcoming results a new market catalyst.

Expected impact

potential volatility; price could move sharply on the actual earnings outcome

Evidence & confidence

Earnings previews provide limited actionable insight; the real impact depends on whether results beat or miss the estimates.

Market effects

The medical device/diagnostic sector may see broader movement if HYPR's results signal trends in small‑cap biotech earnings.

Limited to U.S. small‑cap investors; no broader regional effect expected.

Minimal global impact; relevance confined to HYPR shareholders and niche biotech analysts.

Counterpoint

If the market over‑reacts to a modest miss, a contrarian could buy on the dip expecting a quick rebound.

Key entities

  • Hyperfine, Inc.

    US‑listed medical‑device firm (NASDAQ: HYPR) reporting Q3'26 earnings.

Related articles

$HYPRMed

What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Hyperfine (HYPR) reported $13.8M revenue for the first nine months, up 66% YoY, with 36 systems sold. Management maintained its revenue forecast, citing capital equipment deal sizes and visibility. The company discussed its 'land-and-expand' strategy in health systems and progress in contrast imaging studies. Hyperfine also expanded internationally and explored new markets like memory clinics and wellness.

$HYPRMed

Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2026 Financial Results GUILFORD, Conn.--(BUSINESS WIRE)--November 9, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portab

$HYPRMedAI 9/10

Hyperfine expects Q3 revenue of $6M; shares jump 9%

Hyperfine HYPR reported preliminary Q3 2026 revenue of $6.0M, beating estimates and up 53% sequentially. Shares rose 9% premarket. Net cash burn improved 29% QoQ. Full-year revenue guidance remains $20M-$22M, with cash burn expected to decline 10% YoY. Results will be detailed on Nov 9, 2026.

$HYPRMed

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

$HYPRMedAI 8/10

Hyperfine (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.